Recent Advances in the Development of New Antibiotics and Alternative Anti-infective Therapies
Nadendla Sridivya *
Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P, India.
P. Sailaja
Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P, India.
Y. Prapurnachandra
Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P, India.
*Author to whom correspondence should be addressed.
Abstract
The growing problem of antibiotic resistance has become one of the most serious global health challenges of the 21st century. Many disease-causing bacteria have developed resistance to existing antibiotics, making common infections harder to treat and increasing the risk of severe illness and death. To address this, researchers are focusing on developing new antibiotics and exploring alternative therapies. The development of new antibiotics involves finding novel compounds, modifying existing drugs, and identifying new bacterial targets to overcome resistance mechanisms. However, antibiotic discovery is slow, expensive, and often faces regulatory and economic challenges. As a result, alternative therapies are gaining attention. These include bacteriophage therapy, which uses viruses to attack specific bacteria; antimicrobial peptides that destroy bacterial cell membranes; probiotics that restore healthy microbiota; and immune-based treatments that boost the body’s natural defenses. Advances in nanotechnology and gene-editing tools like CRISPR-Cas systems also offer new ways to precisely target and eliminate resistant bacteria. Combating antibiotic resistance requires a combined approach—developing new antibiotics, promoting responsible antibiotic use, and encouraging research into innovative alternatives. Global cooperation among scientists, governments, and health organizations is essential to ensure sustainable progress. By investing in both new and alternative treatments, we can protect public health and maintain effective infection control for future generations.
Keywords: CRISPR-cas system, bacteriophage therapy, immune based treatments, antibiotic resistance